Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in myocardial perfusion imaging to assess coronary artery disease in adult patients, enabling visualization of myocardial blood flow during single‑photon emission computed tomography (SPECT) scans and assisting clinicians in evaluating cardiac function and ischemia.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides reliable sourcing, regulatory support and global logistics to meet the needs of cardiac imaging centres.

Myoview (technetium‑99m tetrofosmin) is used in cardiac imaging to evaluate myocardial perfusion.

Myocardial perfusion imaging: provides images of blood flow to the heart muscle to detect perfusion defects. Coronary artery disease evaluation: helps identify areas of reduced blood flow due to arterial blockages. Ischemic heart disease assessment: assists in diagnosing ischemia during stress testing.

Adverse reactions to Myoview are generally infrequent but may occur following intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache that may last for a short period. - Dizziness: temporary light‑headedness experienced shortly after injection.

Serious or Rare Side Effects: - Allergic reaction: urticaria, bronchospasm, or anaphylaxis requiring immediate medical attention. - Hypotension: significant drop in blood pressure that may cause faintness. - Arrhythmia: new onset cardiac rhythm disturbances observed during monitoring.

When using Myoview, clinicians should observe specific precautions to ensure patient safety and optimal image quality.

Patient selection: verify indication and assess renal function before administration. Allergy assessment: inquire about prior reactions to radiopharmaceuticals or technetium compounds. Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. Concurrent medications: consider potential interference with thyroid uptake agents. Hydration: encourage adequate fluid intake to facilitate renal clearance of the tracer. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with other agents that affect thyroid function or radiotracer distribution.

Major Interactions (Avoid): - Iodine‑containing contrast agents: can block myocardial uptake of technetium‑99m tracers. - Thyroid hormone therapy: may alter tracer biodistribution.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may influence heart rate and affect stress test results. - Calcium channel blockers: can modify myocardial blood flow during imaging. - Vasodilators (e.g., dipyridamole): may enhance tracer uptake and require protocol adjustment.